N-cyclopropyl-4-methyl-3-[2-oxo-3-[(2-pyridinylmethyl)amino]-1(2H)-pyrazinyl]-benzamide | 1095002-33-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-cyclopropyl-4-methyl-3-[2-oxo-3-[(2-pyridinylmethyl)amino]-1(2H)-pyrazinyl]-benzamide
• 英文别名: N-cyclopropyl-4-methyl-3-[2-oxo-3-(pyridin-2-ylmethylamino)pyrazin-1-yl]benzamide
• CAS: 1095002-33-7
• 化学式: C₂₁H₂₁N₅O₂
• 分子量: 375.43
• InChiKey: VBBXXBFJGMMHAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  86.7
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT D'ÉTATS LIÉS AU STRESS
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2010137738A1

  公开（公告）日：2010-12-02

  The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R1 and R2, each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R3 represents a lower alkynyl group or the like; R4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.

  本发明提供了一种新颖的杂环化合物。一种由通式（1）表示的杂环化合物，其中，R1和R2分别独立表示氢；苯基较低烷基基团，可能在苯环和/或较低烷基基团上具有从较低烷基基团等组成的取代基；或环C3-C8烷基较低烷基基团；或类似物；R3表示较低炔基基团或类似物；R4表示可能具有从1,3,4-噁二唑基团（例如，卤素）或从吡啶基团等组成的取代基的苯基团；所述杂环基可能具有至少一个从较低烷氧基等选择的取代基或其盐。
• AMIDINOANILINE DERIVATIVE
  申请人：AJINOMOTO CO., INC.

  公开号：US20130023563A1

  公开（公告）日：2013-01-24

  Provided are a novel amidine derivative having an activated blood coagulation factor X inhibitory activity, a production method thereof, a production intermediate therefor, and a pharmaceutical composition containing the amidine derivative. An amidinoaniline derivative represented by the following formula (1-1) or a pharmaceutically acceptable salt thereof: , and a pharmaceutical composition containing the amidinoaniline derivative or a pharmaceutically acceptable salt thereof.

  提供了一种具有活化血凝血因子X抑制活性的新型胍衍生物，其制备方法，制备中间体以及含有该胍衍生物的药物组合物。所述胍胺苯衍生物如下式（1-1）所代表或其药用可接受的盐：<在式（1-1）中，每个符号如描述中定义>，以及含有该胍胺苯衍生物或其药用可接受的盐的药物组合物。
• Fungicidal Compounds, Method For the Production Thereof, And Use Thereof To Combat Damaging Fungi, And Agents Comprising The Same
  申请人：Rheinheimer Joachim

  公开号：US20100304966A1

  公开（公告）日：2010-12-02

  Compounds of the formula I in which the substituents have the meaning given in the description, processes for preparing these compounds, compositions comprising them and their use for controlling harmful fungi.

  该式化合物I的取代基在描述中给出其含义，制备这些化合物的方法，包含它们的组合物以及它们用于控制有害真菌的用途。
• 2-Heteroaryl carboxamides
  申请人：Luithle Joachim

  公开号：US20060160877A1

  公开（公告）日：2006-07-20

  The invention relates to novel 2-heteroaryl carboxamides and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.

  本发明涉及新的2-杂环芳基羧酰胺及其用于制备治疗和/或预防疾病以及改善感知、注意力、学习和/或记忆的药物。
• Tissue Factor Production Inhibitor
  申请人：Terasaka Naoki

  公开号：US20080255111A1

  公开（公告）日：2008-10-16

  A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.

  一种药物，具有抑制组织因子产生活性，包括LXR配体作为活性成分;以及用于治疗和/或预防血管再狭窄的药物，包括血管成形术，动脉内膜切除术，经皮冠状动脉成形术（PTCA）或支架植入术后的治疗和/或预防，或治疗和/或预防血液凝固疾病，包括稳定或不稳定的心绞痛，心血管和脑血管疾病，包括伴随糖尿病的血栓栓塞形成疾病，溶栓后再栓塞，脑缺血发作，梗塞，中风，缺血性痴呆，周围动脉疾病，主动脉冠状动脉旁路使用期间的血栓栓塞形成疾病，肾小球硬化，肾脏栓塞，肿瘤或癌症转移，其中包括LXR配体作为活性成分。